Developer docs
API playgroundTry for free, no card

Search company profiles

Avidity Biosciences

Full company profile

uuid00006dm

Namestring
Avidity Biosciences
Legal namestring
Avidity Biosciences, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Avidity Biosciences was a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2012 to develop a new class of RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugates (AOC) platform. The platform combines the cell-type specificity of monoclonal antibodies with the precision of oligonucleotide therapies to enable targeted delivery of RNA payloads into muscle tissue, a capability not previously demonstrated in clinical development. The company advanced three clinical-stage programs targeting rare genetic muscle diseases with no or limited approved disease-modifying treatments: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) in Phase 3, delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD) in Phase 1/2, and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy mutations amenable to exon 44 skipping in Phase 2.

The company's go-to-market motion during its independent existence was research-driven rather than commercial, relying on peer-reviewed publications (including The New England Journal of Medicine), medical conference presentations, patient advocacy engagement, and medical science liaisons. Distribution of investigational therapies occurred exclusively through global clinical trials (HARBOR, FORTITUDE, EXPLORE44) and a US Managed Access Program administered with Clinigen Group. Avidity raised over $1.7 billion in capital across multiple public offerings and private placements between 2022 and 2026 to fund clinical development, regulatory preparation, and pre-commercial infrastructure.

On February 27, 2026, Novartis AG completed its acquisition of Avidity for approximately $12 billion at $72.00 per share in cash, making Avidity an indirect wholly owned subsidiary. Prior to closing, Avidity spun off its early-stage precision cardiology programs into Atrium Therapeutics, which launched as an independent public company with approximately $270 million in cash. Following the acquisition, Avidity's commercial trajectory will be executed through Novartis's global pharmaceutical sales infrastructure, with the parent projecting combined peak annual sales of $5-9 billion from the acquired rare disease assets by the early 2030s.

Short descriptiontext

Avidity Biosciences was a clinical-stage biopharmaceutical company developing RNA therapeutics for rare muscle diseases using its proprietary Antibody Oligonucleotide Conjugates platform, serving patients with DM1, FSHD, and DMD. Acquired by Novartis AG in February 2026 for approximately $12 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA therapeutics, rare muscle diseases, oligonucleotide conjugates, neuromuscular disorder treatments, biopharmaceutical drug development
Industry4 codes
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease RNA Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1RNA Therapeutic Development and Commercialization
TypeOne Time License
Description

Pre-commercial stage company developing RNA therapeutics for rare muscle diseases. Revenue will be generated through product sales following regulatory approval. The company has raised over $1.7 billion in capital through multiple public and private offerings before being acquired by Novartis for $12 billion in February 2026.

stocktitan.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Avidity Biosciences develops investigational RNA therapeutics for rare muscle diseases using its proprietary Antibody Oligonucleotide Conjugates (AOC) platform, which combines monoclonal antibody specificity with oligonucleotide precision to deliver RNA payloads to muscle tissue. The clinical pipeline includes three drug candidates: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1, delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy, and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy amenable to exon 44 skipping.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ~40% mean reduction in DMPK mRNA with delpacibart etedesiran
+2 more records
Product overview1 text field

Avidity Biosciences is delivering a new class of RNA therapeutics through its proprietary Antibody Oligonucleotide Conjugates (AOC) platform, which combines the specificity of monoclonal antibodies with the precision of oligonucleotide therapies. The company's clinical development portfolio includes three AOC programs for rare muscle diseases: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) currently in Phase 3 HARBOR trial; delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD) in Phase 1/2 FORTITUDE trial; and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD) exon 44 skipping in Phase 2 EXPLORE44-OLE study. The company was acquired by Novartis AG in February 2026 for approximately $12 billion, with its early-stage precision cardiology programs spun off into Atrium Therapeutics.

Product and service3 records
1Delpacibart etedesiran (del-desiran, AOC 1001)
CategoryInvestigational RNA therapeutic (DM1)
Description

Investigational lead product candidate using the AOC platform for the treatment of myotonic dystrophy type 1 (DM1). Designed to reduce DMPK mRNA and improve myotonia, muscle strength, mobility, and patient-reported outcomes. Currently in the global Phase 3 HARBOR trial with positive MARINA Phase 1/2 results published in The New England Journal of Medicine demonstrating approximately 40% mean reduction in DMPK mRNA.

2Delpacibart braxlosiran (del-brax, AOC 1020)
CategoryInvestigational RNA therapeutic (FSHD)
Description

Investigational AOC designed to treat facioscapulohumeral muscular dystrophy (FSHD) by targeting DUX4 gene expression. The FORTITUDE Phase 1/2 trial met its primary endpoint with reduction in KHDC1 plasma concentration and showed reduction in creatine kinase biomarker levels.

3Delpacibart zotadirsen (del-zota, AOC 1044)
CategoryInvestigational RNA therapeutic (DMD)
Description

Investigational AOC designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping. Demonstrated statistically significant increases in exon skipping and dystrophin levels in the Phase 1/2 EXPLORE44 study. First of multiple AOCs in development for DMD.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthersAnnounced on2026-02-27
Description

Atrium Therapeutics was spun off from Avidity Biosciences in connection with the Novartis acquisition in February 2026. The company launched as an independent publicly traded entity focused on RNA therapeutics for rare genetic cardiomyopathies, taking on Avidity's early-stage precision cardiology programs and the RNA ticker symbol. Atrium launched with approximately $270 million in cash.

2Bristol Myers Squibb
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Bristol Myers Squibb collaboration with Atrium Therapeutics (spun off from Avidity) generated a $15 million milestone payment in Q1 2026, driving collaboration revenue to $19.6 million for the quarter.

prnewswire.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Clinigen Group serves as the MAP coordinator for Avidity's investigational therapy delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy patients amenable to exon 44 skipping in the United States. Requests for information on the DMD44 Managed Access Program are directed to usmapcoordinators@clinigengroup.com.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Dyne Therapeutics is the closest direct peer to Avidity, developing antibody-conjugated oligonucleotides (FORCE platform) for muscle diseases including DM1, FSHD, and DMD. Both companies pursue targeted RNA delivery to muscle tissue using antibody-oligonucleotide conjugate chemistry, with overlapping clinical programs and competitive readouts.

TypeDirect peer
Description

Sarepta is the established leader in DMD therapeutics, with approved exon-skipping PMOs (eteplirsen, golodirsen, casimersen) and ELEVIDYS gene therapy. It is a direct competitor in the DMD44 patient population that del-zota targets and in adjacent muscle-disease indications.

TypeEmerging player
Description

PepGen develops enhanced delivery oligonucleotides (EDOs) for neuromuscular diseases including DM1 and DMD. Its cell-penetrating peptide conjugates compete with Avidity's antibody conjugates for the same tissue-targeting problem in muscle.

TypeEmerging player
Description

Wave Life Sciences develops stereopure oligonucleotide therapeutics (PRISM platform) with programs in DM1, DMD, and Huntington's disease. It competes in the same oligonucleotide therapeutic modality as Avidity's AOC payload chemistry.

TypeBroad incumbent
Description

Ionis is the pioneer and largest antisense oligonucleotide (ASO) company, with deep oligonucleotide chemistry expertise and a broad pipeline across neuromuscular, neurological, and metabolic diseases. Its oligonucleotide platform overlaps with Avidity's payload chemistry while lacking Avidity's antibody-targeting layer.

TypeBroad incumbent
Description

Alnylam is the leading RNAi therapeutics company with approved siRNA products (Onpattro, Givlaari, Oxlumo, Amvuttra). While it uses a different RNA modality (siRNA vs. AOC), it shares the rare-disease commercial model and oligonucleotide-based therapeutic paradigm with Avidity.

TypeEmerging player
Description

Solid Biosciences develops gene therapies and oligonucleotide approaches for Duchenne muscular dystrophy and other neuromuscular diseases. It overlaps with Avidity's DMD44 program via a different delivery modality (AAV gene therapy).

TypeBroad incumbent
Description

BioMarin is an established rare-disease biopharma with multiple approved enzyme replacement and gene therapies. It provides a comparable commercial model for orphan neuromuscular and rare-disease launches that Avidity/Novartis will pursue with del-desiran, del-brax, and del-zota.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avidity Biosciences

Rare Disease RNA Therapeuticsaviditybiosciences.com

Avidity Biosciences was a clinical-stage biopharmaceutical company developing RNA therapeutics for rare muscle diseases using its proprietary Antibody Oligonucleotide Conjugates platform, serving patients with DM1, FSHD, and DMD. Acquired by Novartis AG in February 2026 for approximately $12 billion.

What Avidity Biosciences does

Avidity Biosciences was a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2012 to develop a new class of RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugates (AOC) platform. The platform combines the cell-type specificity of monoclonal antibodies with the precision of oligonucleotide therapies to enable targeted delivery of RNA payloads into muscle tissue, a capability not previously demonstrated in clinical development. The company advanced three clinical-stage programs targeting rare genetic muscle diseases with no or limited approved disease-modifying treatments: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) in Phase 3, delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD) in Phase 1/2, and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy mutations amenable to exon 44 skipping in Phase 2.

The company's go-to-market motion during its independent existence was research-driven rather than commercial, relying on peer-reviewed publications (including The New England Journal of Medicine), medical conference presentations, patient advocacy engagement, and medical science liaisons. Distribution of investigational therapies occurred exclusively through global clinical trials (HARBOR, FORTITUDE, EXPLORE44) and a US Managed Access Program administered with Clinigen Group. Avidity raised over $1.7 billion in capital across multiple public offerings and private placements between 2022 and 2026 to fund clinical development, regulatory preparation, and pre-commercial infrastructure.

On February 27, 2026, Novartis AG completed its acquisition of Avidity for approximately $12 billion at $72.00 per share in cash, making Avidity an indirect wholly owned subsidiary. Prior to closing, Avidity spun off its early-stage precision cardiology programs into Atrium Therapeutics, which launched as an independent public company with approximately $270 million in cash. Following the acquisition, Avidity's commercial trajectory will be executed through Novartis's global pharmaceutical sales infrastructure, with the parent projecting combined peak annual sales of $5-9 billion from the acquired rare disease assets by the early 2030s.

Avidity Biosciences firmographics

Firmographics
Name
Avidity Biosciences
Legal name
Avidity Biosciences, Inc.
Website
https://aviditybiosciences.com
Company type
Public
Founded year
2012
Operating status
Acquired
Headcount range
251–500 employees
Short description
Avidity Biosciences was a clinical-stage biopharmaceutical company developing RNA therapeutics for rare muscle diseases using its proprietary Antibody Oligonucleotide Conjugates platform, serving patients with DM1, FSHD, and DMD. Acquired by Novartis AG in February 2026 for approximately $12 billion.
Ownership category
akta.pro rank

Avidity Biosciences industry classification

Industry
Product category
Rare Disease RNA Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA therapeutics
  • Rare muscle diseases
  • Oligonucleotide conjugates
  • Neuromuscular disorder treatments
  • Biopharmaceutical drug development

Where Avidity Biosciences is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Avidity Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. RNA Therapeutic Development and Commercialization: Pre-commercial stage company developing RNA therapeutics for rare muscle diseases. Revenue will be generated through product sales following regulatory approval. The company has raised over $1.7 billion in capital through multiple public and private offerings before being acquired by Novartis for $12 billion in February 2026.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Avidity Biosciences product offering

Product offering

Core offering

Avidity Biosciences develops investigational RNA therapeutics for rare muscle diseases using its proprietary Antibody Oligonucleotide Conjugates (AOC) platform, which combines monoclonal antibody specificity with oligonucleotide precision to deliver RNA payloads to muscle tissue. The clinical pipeline includes three drug candidates: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1, delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy, and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy amenable to exon 44 skipping.

Product overview

Avidity Biosciences is delivering a new class of RNA therapeutics through its proprietary Antibody Oligonucleotide Conjugates (AOC) platform, which combines the specificity of monoclonal antibodies with the precision of oligonucleotide therapies. The company's clinical development portfolio includes three AOC programs for rare muscle diseases: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) currently in Phase 3 HARBOR trial; delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD) in Phase 1/2 FORTITUDE trial; and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD) exon 44 skipping in Phase 2 EXPLORE44-OLE study. The company was acquired by Novartis AG in February 2026 for approximately $12 billion, with its early-stage precision cardiology programs spun off into Atrium Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Delpacibart etedesiran (del-desiran, AOC 1001) Investigational lead product candidate using the AOC platform for the treatment of myotonic dystrophy type 1 (DM1). Designed to reduce DMPK mRNA and improve myotonia, muscle strength, mobility, and patient-reported outcomes. Currently in the global Phase 3 HARBOR trial with positive MARINA Phase 1/2 results published in The New England Journal of Medicine demonstrating approximately 40% mean reduction in DMPK mRNA.
  • Delpacibart braxlosiran (del-brax, AOC 1020) Investigational AOC designed to treat facioscapulohumeral muscular dystrophy (FSHD) by targeting DUX4 gene expression. The FORTITUDE Phase 1/2 trial met its primary endpoint with reduction in KHDC1 plasma concentration and showed reduction in creatine kinase biomarker levels.
  • Delpacibart zotadirsen (del-zota, AOC 1044) Investigational AOC designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping. Demonstrated statistically significant increases in exon skipping and dystrophin levels in the Phase 1/2 EXPLORE44 study. First of multiple AOCs in development for DMD.

Quantifiable outcome

  • ~40% mean reduction in DMPK mRNA with delpacibart etedesiran
  • +2 more outcomes

Companies that use Avidity Biosciences

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Avidity Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Avidity Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • Atrium TherapeuticsminorOthers · 27 February 2026Atrium Therapeutics was spun off from Avidity Biosciences in connection with the Novartis acquisition in February 2026. The company launched as an independent publicly traded entity focused on RNA therapeutics for rare genetic cardiomyopathies, taking on Avidity's early-stage precision cardiology programs and the RNA ticker symbol. Atrium launched with approximately $270 million in cash.
  • Bristol Myers SquibbminorStrategic or Co-development PartnerBristol Myers Squibb collaboration with Atrium Therapeutics (spun off from Avidity) generated a $15 million milestone payment in Q1 2026, driving collaboration revenue to $19.6 million for the quarter.
  • Clinigen GroupminorChannel Partner/ Reseller/ DistributorClinigen Group serves as the MAP coordinator for Avidity's investigational therapy delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy patients amenable to exon 44 skipping in the United States. Requests for information on the DMD44 Managed Access Program are directed to usmapcoordinators@clinigengroup.com.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Avidity Biosciences competitors and assessment

Company assessment

Direct peers

  • Dyne Therapeutics: Dyne Therapeutics is the closest direct peer to Avidity, developing antibody-conjugated oligonucleotides (FORCE platform) for muscle diseases including DM1, FSHD, and DMD. Both companies pursue targeted RNA delivery to muscle tissue using antibody-oligonucleotide conjugate chemistry, with overlapping clinical programs and competitive readouts.
  • Sarepta Therapeutics: Sarepta is the established leader in DMD therapeutics, with approved exon-skipping PMOs (eteplirsen, golodirsen, casimersen) and ELEVIDYS gene therapy. It is a direct competitor in the DMD44 patient population that del-zota targets and in adjacent muscle-disease indications.

Emerging players

  • PepGen: PepGen develops enhanced delivery oligonucleotides (EDOs) for neuromuscular diseases including DM1 and DMD. Its cell-penetrating peptide conjugates compete with Avidity's antibody conjugates for the same tissue-targeting problem in muscle.
  • Wave Life Sciences: Wave Life Sciences develops stereopure oligonucleotide therapeutics (PRISM platform) with programs in DM1, DMD, and Huntington's disease. It competes in the same oligonucleotide therapeutic modality as Avidity's AOC payload chemistry.
  • Solid Biosciences: Solid Biosciences develops gene therapies and oligonucleotide approaches for Duchenne muscular dystrophy and other neuromuscular diseases. It overlaps with Avidity's DMD44 program via a different delivery modality (AAV gene therapy).

Broad incumbents

  • Ionis Pharmaceuticals: Ionis is the pioneer and largest antisense oligonucleotide (ASO) company, with deep oligonucleotide chemistry expertise and a broad pipeline across neuromuscular, neurological, and metabolic diseases. Its oligonucleotide platform overlaps with Avidity's payload chemistry while lacking Avidity's antibody-targeting layer.
  • Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company with approved siRNA products (Onpattro, Givlaari, Oxlumo, Amvuttra). While it uses a different RNA modality (siRNA vs. AOC), it shares the rare-disease commercial model and oligonucleotide-based therapeutic paradigm with Avidity.
  • BioMarin Pharmaceutical: BioMarin is an established rare-disease biopharma with multiple approved enzyme replacement and gene therapies. It provides a comparable commercial model for orphan neuromuscular and rare-disease launches that Avidity/Novartis will pursue with del-desiran, del-brax, and del-zota.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Avidity Biosciences social profiles

Digital presence

Avidity Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avidity Biosciences leadership team

Management profile

Number of profiles

Profiles10 records

Avidity Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Avidity Biosciences funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avidity Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avidity Biosciences

What does Avidity Biosciences do?

Avidity Biosciences develops investigational RNA therapeutics for rare muscle diseases using its proprietary Antibody Oligonucleotide Conjugates (AOC) platform, which combines monoclonal antibody specificity with oligonucleotide precision to deliver RNA payloads to muscle tissue. The clinical pipeline includes three drug candidates: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1, delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy, and delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy amenable to exon 44 skipping.

Is Avidity Biosciences a public or private company?

Avidity Biosciences is a public company. It is classified as corporate owned and is currently acquired.

When was Avidity Biosciences founded?

Avidity Biosciences was founded in 2012. It employs 251 to 500 people.

Where is Avidity Biosciences based?

Avidity Biosciences is headquartered in San Diego, United States, in the North America region.

How does Avidity Biosciences make money?

One revenue line is on record: RNA Therapeutic Development and Commercialization.

Who are Avidity Biosciences's main competitors?

Direct peers on record are Dyne Therapeutics and Sarepta Therapeutics. Emerging players are PepGen, Wave Life Sciences and Solid Biosciences. Broad incumbents are Ionis Pharmaceuticals, Alnylam Pharmaceuticals and BioMarin Pharmaceutical.

Does Avidity Biosciences have an API?

No public API is recorded for Avidity Biosciences.

What industry is Avidity Biosciences in?

Avidity Biosciences's product category is Rare Disease RNA Therapeutics. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAvidity Biosciences, Inc. (NASDAQ:RNA) Stock Has Average Price Target of $40.80Avidity Biosciences stock has a consensus rating of Moderate Buy with an average 12-month target of $33.00. The company reported Q4 EPS of -$0.25, beating estimates of -$0.81, and revenue of $15.32 million. Analysts forecast a -4.45 EPS for the current year.American Banking and Market NewsAvidity Biosciences (NASDAQ:RNA) Stock Price Target Cut by HC WainwrightHC Wainwright cut its price target on Avidity Biosciences from $25 to $20, keeping a buy rating. The stock opened at $8.26, with a consensus target of $40.80 and a Moderate Buy rating. The company reported Q2 EPS of -$1.18, beating estimates.American Banking and Market NewsAvidity Biosciences (NASDAQ:RNA) Stock Picked Up by Analysts at Roth CapitalRoth Capital initiated coverage on Avidity Biosciences with a buy rating and a $15 price target, implying 82.93% upside. The stock opened at $8.20, and analysts have an average rating of Hold with a $59 target. The company reported Q2 EPS of -$1.18, beating the -$1.42 consensus.MarketBeatAvidity Biosciences (NASDAQ:RNA) Stock Rated Buy in New Coverage at Roth CapitalRoth Capital initiated coverage on Avidity Biosciences with a buy rating and $15 price target, implying 87.5% upside. The company reported Q2 EPS of -$1.18, beating estimates, and revenue of $3.00 million. Hsbc Holdings acquired a new position in the stock.American Banking and Market NewsAvidity Biosciences, Inc. (RNA) – What Are Investment Firms Thinking About This Stock?Avidity Biosciences received an average 'Hold' rating from 16 brokerages, with an average price target of $63.75. The company reported a quarterly loss of $1.18 per share, beating estimates, and revenue of $3.00 million. Several hedge funds bought new stakes in the fourth quarter.MarketBeatAvidity Biosciences, Inc. (RNA) - What Are Researchers Thinking About This Stock?Avidity Biosciences received a consensus 'Hold' rating from 16 analysts, with an average 12-month price target of $63.75. The company reported Q2 EPS of -$1.18, beating estimates of -$1.42, and revenue of $3.00 million versus $0.67 million expected. Analysts expect -$5.08 EPS for the current year.STATIn Duchenne muscular dystrophy, a promising therapy is available to a fortunate fewAvidity Biosciences' experimental drug Del-zota, which skips a gene segment to produce a functional protein, is under FDA review for Duchenne muscular dystrophy. Only about 7% of U.S. patients—roughly 900—are eligible, though the approach could benefit about 70% of the 10,000 to 15,000 affected males.MarketScreenerMajor Novartis shareholder calls for board shake-up after drug trial setbacksNovartis shareholder David Samra called for a board shake-up after the company's shares fell over 10% following a failed drug trial. He urged chairman Giovanni Caforio to improve oversight of acquisitions, citing a $12 billion Avidity deal that failed a late-stage study. Samra also criticized the compensation structure for relying on adjusted performance measures.Investing.comNovartis twin drug setbacks pile pressure on pipeline and CEO By ReutersNovartis said its experimental drug del-desiran failed a Phase III study for myotonic dystrophy, sending shares down about 9%. The setback is the second major trial failure in days, adding pressure on CEO Vas Narasimhan and the company's pipeline. Novartis reiterated full-year guidance despite the setback.pharmaphorumNovartis falls sharply on another major R&D setbackNovartis's del-desiran failed to show efficacy in myotonic dystrophy type 1 in the HARBOR trial, missing its primary endpoint. The company's share price fell 9% on the news, and the setback could affect confidence in other Avidity Bio-acquired antibody-oligonucleotide conjugates. Novartis maintained its 5%-6% revenue growth forecast for 2025-2030.